Cerebrospinal fluid monoamine metabolites in narcolepsy and hypersomnia

Authors

  • Kym F. Faull PhD,

    1. Sleep Disorders Clinic, Stanford University School of Medicine, Stanford, CA 94305
    Search for more papers by this author
  • Dr Christian Guilleminault MD,

    Corresponding author
    1. Nancy Pritzker Laboratory of Behavioral Neurochemistry, Stanford University School of Medicine, Stanford, CA 94305
    • Sleep Disorders Clinic, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305
    Search for more papers by this author
  • Philip A. Berger MD,

    1. Mental Health Clinical Research Center, Palo Alto Veterans Administration Hospital, and the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305
    Search for more papers by this author
  • Jack D. Barchas MD

    1. Sleep Disorders Clinic, Stanford University School of Medicine, Stanford, CA 94305
    Search for more papers by this author

Abstract

Two groups of patients with the common complaint of excessive daytime sleepiness were examined. One group fulfilled the criteria for narcolepsy. The other had the sole symptom of excessive daytime sleepiness, confirmed by sleep latency tests, which was unaccompanied by systemic illness. Spinal fluid examinations for homovanillic acid, 3,4-dihydroxyphenylacetic acid, 3-methoxy-4-hydroxyphenylethylene glycol, and 5-hydroxyindoleacetic acid were carried out before and after administration of probenecid on the 20 patients and 40 controls. Probenecid-corrected accumulation of the dopamine metabolites was significantly increased in each of the patient groups, suggesting an association between pathological sleepiness and elevated dopamine turnover in the central nervous system.

Ancillary